(NYSE:BSX) Boston Scientific Corporation Breaks 52 Week High Record

Boston Scientific Corporation (NYSE:BSX)

June 11th, 2019

Amidst falling markets Boston Scientific Corporation fell ($0.29) Tuesday, down 0.70%, closing at $41.17. Despite the drop in price it hit a new 52 week high of $42.00.

BSX was outperformed by the rest of the Healthcare sector which went down only -0.25%.

Boston Scientific Corporation is listed on the S&P 500 index, and was one of 264 stocks that slumped today. Weighted by market cap, BSX represents about 0.23% of the S&P 500.

Results from 25 analysts points to the possibility that Boston Scientific Corporation could go up somewhat (5.10%), while Finbox has calculated (with medium uncertainty) a fair value price of $37.98.

Market Sectors

The market sectors were mixed Tuesday with a majority of the sectors trending up. Consumer Staples saw the biggest increase of the day (0.41%), while the Industrials sector saw the biggest drop (-0.90%). Information Technology has seen the biggest year-to-date gain of 23.75%.

Industrials and Utilities both saw turn-arounds from their five day positive performances with Industrials dropping -0.90%.

Sector Breakdown

  • Consumer Staples, up 0.41%.
  • Consumer Discretionary, up 0.33%.
  • Communication Services, up 0.29%.
  • Real Estate, up 0.18%.
  • Energy, up 0.12%.
  • Information Technology, up 0.02%.
  • Financials, stayed even 0.00%.
  • Materials, down -0.07%.
  • Healthcare, down -0.25%.
  • Utilities, down -0.69%.
  • Industrials, down -0.90%.

Boston Scientific Corporation Info

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems. It also provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy systems, wires, and stents to treat venous diseases; and peripheral embolization devices, microcatheters, and drainage catheters to treat various cancers. In addition, the company offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to treat abnormalities; remote patient management system; implantable cardiac resynchronization therapy pacemaker systems; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, mapping system, and other accessories. Further, it provides products to diagnose and treat diseases of the gastrointestinal and pulmonary conditions; devices to diagnose, treat, and palliate pulmonary diseases within the airway and lungs; products to treat various urological and pelvic conditions; deep brain stimulation systems for the treatment of parkinson’s disease, tremor, and intractable primary and secondary dystonia; and spinal cord stimulator systems for the management of chronic pain. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.

All amounts in USD unless otherwise indicated

BSX daily update
BSX daily update

Via UnSplash

Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.

Tell us what you think